MentionFox
Home › Executive changes › CNS Pharmaceuticals, Inc.
Leadership changes · CNSP · SEC Form 8-K, Item 5.02

Leadership changes at CNS Pharmaceuticals, Inc. (2026)

Before you join, sell to or invest in CNS Pharmaceuticals, Inc.

MentionFox check on CNS Pharmaceuticals, Inc.: no red flags found in 3 sources (checked 14 November 2026). mentionfox.com/c/executive-changes/cns-pharmaceuticals

Check CNS Pharmaceuticals, Inc. before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about CNS Pharmaceuticals, Inc.?

Who joined and who left CNS Pharmaceuticals, Inc. (CNSP)? 3 filings reported from 2026-02-17 to 2026-05-04, each cited to the company's own filing.

As of November 14, 2026, CNS Pharmaceuticals, Inc. has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from February 17, 2026 to May 4, 2026 (Form 8-K, May 4, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

Stonepine Capital Management, LLC also filed stake reports on 17 other companies ↓

Sell to companies like CNS Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Key facts

  • · In / out: Reported · Person: not named in the filing · 8-K, 2026-05-04
  • · In / out: Reported · Person: not named in the filing · 8-K, 2026-03-02
  • · In / out: Reported · Person: not named in the filing · 8-K, 2026-02-17
Changes3
Latest filing2026-05-04

CNS Pharmaceuticals, Inc. reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-02-17 to 2026-05-04. Every row below is cited to the filing it comes from, and this page adds each new change as CNS Pharmaceuticals, Inc. files it.

Also on the record for CNS Pharmaceuticals, Inc.

DateRecordFigureOur pageSource
August 14, 2026Stake report, Schedule 13G/A, by Ikarian Capital, LLC9.9% of the class5%+ stakesSource
May 19, 2026Form D, private offering$22.52M soldForm D pageSource
May 15, 2026Stake report, Schedule 13G/A, by Stonepine Capital Management, LLC9.9% of the class5%+ stakesSource
April 17, 2026Stake report, Schedule 13G, by Ikarian Capital, LLC5.7% of the class5%+ stakesSource
February 13, 2026Stake report, Schedule 13G/A, by Stonepine Capital Management, LLC7.9% of the class5%+ stakesSource
November 14, 2025Stake report, Schedule 13G/A, by Armistice Capital, LLC4.99% of the class5%+ stakesSource
November 4, 2025Stake report, Schedule 13G, by Stonepine Capital Management, LLC5.6% of the class5%+ stakesSource
August 14, 2025Stake report, Schedule 13G, by Armistice Capital, LLC9.99% of the class5%+ stakesSource

Selling to them or working with them? See who runs CNS Pharmaceuticals, Inc. now and the warning signs.

Free to see. No signup.

Keep reading

More on CNS Pharmaceuticals, Inc. and the records around it.

CNS Pharmaceuticals, Inc. elsewhere on the record

Companies that share a holder

Want the whole picture on CNS Pharmaceuticals, Inc.?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on CNS Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on CNS Pharmaceuticals, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    11 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-05-04Reportednot named in the filing8-K, 2026-05-04
2026-03-02Reportednot named in the filing8-K, 2026-03-02
2026-02-17Reportednot named in the filing8-K, 2026-02-17
Selling to CNS Pharmaceuticals, Inc.?

New leaders reset buying decisions — get the Full Report on CNS Pharmaceuticals, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch CNS Pharmaceuticals, Inc.

Hiring for a seat like this?

Find people with the same kind of experience as the senior executive at CNS Pharmaceuticals, Inc., with the record behind each one.

Find candidates like senior executive at CNS Pharmaceuticals, Inc.

Every change, in the filing's words

Filed 2026-05-04 · 8-K

Reported

On May 4, 2026, Jerzy (George) Gumulka resigned as a member of the Company's Board of Directors (the "Board") .

Also stated in this filing

  • Mr. Gumulka's resignation from the Board was not a result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
  • On May 4, 2026, the Board agreed to appoint Michal Fisher as an independent member of the Company's Board.
  • Ms. Fisher is a senior life sciences executive with over 15 years of experience spanning business development, corporate strategy, investor relations, and deal structuring across biotech, pharma, and medtech.
  • She has a proven track record of closing complex licensing transactions, raising capital, and building global partnerships.
  • Ms. Fisher is currently Chief Business Officer at BioGenCell, a biotechnology company developing an autologous cell therapy for no-option Critical Limb-Threatening Ischemia, where she leads BioGenCell's capital raising strategy to support a Phase 3 trial as well as commercial planning.
  • From 2020 to 2025, Ms. Fisher was Head of Corporate Development at LifeSci Partners, an integrated life sciences advisory firm, where she supported business development and growth of the entire LifeSci Partners platform, including LifeSci Advisors, LifeSci Capital, LifeSci Ventures, LifeSci Consulting, and LifeSci Search.
Filed 2026-03-02 · 8-K

Reported

On February 26, 2026, CNS Pharmaceuticals, Inc. (the "Company") entered into an employment agreement (the "Employment Agreement") with Lynne Kelley to serve as the Company's Chief Medical Officer effective March 2, 2026.

Also stated in this filing

  • The Employment Agreement provides for an initial annual base salary of $450,000, eligibility for an annual bonus with a target equal to 40% of base salary based on goals approved by the Compensation Committee, and eligibility for annual equity grants under the Company's stock incentive plans, in each case as determined by the Compensation Committee of the Board of Directors.
  • The Employment Agreement also provides for an initial grant of 9,500 restricted stock units, vesting as follows: 25% on the six-month anniversary of the effective date, 25% on the twelve-month anniversary of the effective date, and the remaining 50% in twelve quarterly installments thereafter, subject to continued employment.
  • Dr. Kelley is entitled to participate in the Company's benefit plans and programs for similarly situated executives, expense reimbursement in accordance with Company policy, and other standard benefits.
  • Dr. Kelley, age 63, most recently served as Chief Medical Officer of Tissium, Inc., a clinical-stage biotechnology company, from September 2024 to February 2026.
  • From May 2022 to February 2026, Dr. Kelley served as Founder and Chief Executive Officer and Chief Medical Officer of Xenthera, Inc., a clinical-stage oncology company, and continues to serve as an advisor for the assets.
Filed 2026-02-17 · 8-K

Reported

On February 10, 2026, CNS Pharmaceuticals, Inc. (the "Company") entered into an employment agreement (the "O'Loughlin Employment Agreement") with Steve O'Loughlin to serve as the Company's Chief Financial Officer effective March 2, 2026.

Also stated in this filing

  • The O'Loughlin Employment Agreement provides for an initial annual base salary of $450,000, eligibility for an annual bonus with a target equal to 40% of base salary based on goals approved by the Compensation Committee, and eligibility for annual equity grants under the Company's stock incentive plans, in each case as determined by the Compensation Committee of the Board of Directors.
  • The O'Loughlin Employment Agreement also provides for an initial grant of 9,500 restricted stock units, vesting as follows: 25% on the six-month anniversary of the effective date, 25% on the twelve-month anniversary of the effective date, and the remaining 50% in twelve quarterly installments thereafter, subject to continued employment.
  • Mr. O'Loughlin is entitled to participate in the Company's benefit plans and programs for similarly situated executives, expense reimbursement in accordance with Company policy, and other standard benefits.
  • Mr. O'Loughlin, age 41, served as Chief Financial Officer of Actinium Pharmaceuticals, Inc. from August 2020 until February 2026, and as its Principal Financial Officer from May 2017 to August 2020.
  • Mr. O'Loughlin joined Actinium Pharmaceuticals, Inc. in October 2015 as Vice President, Finance and Corporate Development.

Tools for this story

Each opens in a new tab, filled in for CNS Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/cns-pharmaceuticals
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
What changed at the top of CNS Pharmaceuticals, Inc.? (2026). MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/cns-pharmaceuticals